Skip to content

Efficacy of the nutrients supplement "AMP01" for the fatigue of the hemodialysis patients

Efficacy of the nutrients supplement "AMP01" for the fatigue of the hemodialysis patients - Efficacy of "AMP01" for the fatigue of the hemodialysis patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000001055
Enrollment
200
Registered
2008-03-01
Start date
2008-03-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dialysis Patients

Interventions

One bottle (50 ml) of the nutrients supplement &quot
AMP01&quot
is to be administered three times a week just after hemodialysis sessions for 12 weeks. The test food is lightly yellow drink containing carnitine 500mg, CoQ10 30mg, oligosaccharide 5g, zinc 8mg, vit

Sponsors

Osaka City University Medical School
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Patients who are equal or more than 30-year-old and less than 70 year-old at the time of getting the Informed consent (2) Patients undergoing regular afternoon or night hemodialysis (3) Hemodialysis duration is more than one year (4) Patients who receive hemodialysis three times a week (5) Patients who are capable of understanding the study, and those who can give written informed consents (6) Patients who can adhere instructions

Exclusion criteria

Exclusion criteria: (1) Patients who are taking nutrients supplements. If the patients can stop taking the supplements two weeks before the study, the patients do not meet exclusion criteria. (2) Patients who receive vitamin compound (except Vitamin D) for treatment, or take OTC drugs for vitamine supplementation. If the patients can stop the treatment two weeks before the study, the patients do not meet exclusion criteria. (3) During the pregnancy or nursing , or patients to be pregnant during the study period (4) patients who participated in other clinical trials for food or drug within the past three months (5)Patients with allergy against constituents of the supplement (6) Others

Design outcomes

Primary

MeasureTime frame
Acceleration plethysmogram, fatigue markers (alpha-MSH, ACTH, cortisol, HHV6, 7), questionnaires for acute and chronic fatigue, questionnaires for QOL (KDQOL-SF).

Countries

Japan

Contacts

Public ContactHisako Fujii

Osaka City University Hospital Center for Drug & Food Clinical Evaluation

hfujii@med.osaka-cu.ac.jp06-6645-3443

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026